Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022
Report Details
Antibacterial medicines - discover performance and commercial prospects of companies
How are leading companies in the antibacterial drugs market performing? Visiongain's new report gives you data, analyses and revenue predictions for antibacterial manufacturers.
See how top companies worldwide are performing and where they are heading. You assess their technologies, products and commercial prospects to 2022.
In our study you find analytical profiles for leading antibiotics producers. The work shows product ranges, R&D and sales prospects, with revenue forecasts from 2012 to 2022:
The report covers leading pharmaceutical players, specialty companies and emerging organisations. Also, you find companies grouped by region of origin:
Antibacterial drug producers: commercial outlook from 2012
Where is the antibiotics market heading? Many opportunities exist in that industry and market, particularly with the development of new classes of antibacterial drug. In particular, treatments targeting C. difficile and MRSA infections will make a difference to 2022.
Patent expiries will challenge antibiotic manufacturers throughout this decade, with generic pharmaceutical sales prominent and growing. Companies will use product lifecycle management to reduce declines of brands and stimulate their sales, our analysis shows.
What about product launches, new drug classes and expanded indications? The antibacterial R&D pipeline has limitations but holds promise. You find out how leading companies can contribute to our predicted growth and renewal of the market to 2022.
In 2012, more than 50 product candidates are in clinical trials. There are many opportunities for collaborations and in-licensing. Many under-met treatment needs exist.
Which companies are best placed to harness opportunities in the discovery, development, manufacturing and marketing of antibacterial medicines? Our study shows you and explains.
Company analyses, revenue forecasts, R&D and discussions of industry prospects
In visiongain's report you find historical revenues, sales predictions, growth rates and market breakdowns. Also, you see discussions of companies, product portfolios, R&D, commercial news and revenue potentials. You receive 95 tables and 66 charts.
Ten ways Top 20 Antibacterial Drug Manufacturers 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
Gain research and analysis on antibacterial drug producers now
Our study is for everybody needing industry and market analyses of antibacterial drug developers and manufacturers. You find data, trends and predictions there. Please order that report now.
Antibacterial medicines - discover performance and commercial prospects of companies
How are leading companies in the antibacterial drugs market performing? Visiongain's new report gives you data, analyses and revenue predictions for antibacterial manufacturers.
See how top companies worldwide are performing and where they are heading. You assess their technologies, products and commercial prospects to 2022.
In our study you find analytical profiles for leading antibiotics producers. The work shows product ranges, R&D and sales prospects, with revenue forecasts from 2012 to 2022:
- Pfizer
- GSK
- Merck & Co.
- Novartis
- Bayer
- J&J
- Cubist Pharmaceuticals
- AstraZeneca
- Abbott Laboratories
- Medicis
- Coverage of 10 other leading manufacturers and four top emerging companies.
The report covers leading pharmaceutical players, specialty companies and emerging organisations. Also, you find companies grouped by region of origin:
- The US
- Europe
- Japan.
Antibacterial drug producers: commercial outlook from 2012
Where is the antibiotics market heading? Many opportunities exist in that industry and market, particularly with the development of new classes of antibacterial drug. In particular, treatments targeting C. difficile and MRSA infections will make a difference to 2022.
Patent expiries will challenge antibiotic manufacturers throughout this decade, with generic pharmaceutical sales prominent and growing. Companies will use product lifecycle management to reduce declines of brands and stimulate their sales, our analysis shows.
What about product launches, new drug classes and expanded indications? The antibacterial R&D pipeline has limitations but holds promise. You find out how leading companies can contribute to our predicted growth and renewal of the market to 2022.
In 2012, more than 50 product candidates are in clinical trials. There are many opportunities for collaborations and in-licensing. Many under-met treatment needs exist.
Which companies are best placed to harness opportunities in the discovery, development, manufacturing and marketing of antibacterial medicines? Our study shows you and explains.
Company analyses, revenue forecasts, R&D and discussions of industry prospects
In visiongain's report you find historical revenues, sales predictions, growth rates and market breakdowns. Also, you see discussions of companies, product portfolios, R&D, commercial news and revenue potentials. You receive 95 tables and 66 charts.
Ten ways Top 20 Antibacterial Drug Manufacturers 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
- Assess 20 leading antibacterial drug manufacturers, discovering their activities and outlooks from 2012
- Discover overall world market and submarket revenue forecasts to 2022
- Receive analyses of leading companies, seeing revenue forecasts to 2022
- View a comparative analysis of trends among antibacterial manufacturers
- Find existing revenues and operational data for leading companies
- Review pipeline developments, assessing R&D trends and potential
- Analyse recent licensing deals and acquisitions
- Investigate competition and opportunities influencing sales
- Review prospects for emerging companies and antimicrobial specialists
- Find out what will stimulate and restrain the industry and market from 2012.
Gain research and analysis on antibacterial drug producers now
Our study is for everybody needing industry and market analyses of antibacterial drug developers and manufacturers. You find data, trends and predictions there. Please order that report now.
1. EXECUTIVE SUMMARY
1.1 Leading Antibacterial Drug Manufacturers: Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.4.1 Drugs Considered for this Report
1.4.1.1 Ophthalmic and Dermatologic Antibacterials
1.4.2 The Chinese Antibacterial Drugs Market
1.5 Terminology Used in this Report
2. AN INTRODUCTION TO THE ANTIBACTERIAL DRUGS MARKET
2.1 Bacterial Infections and Antibacterial Drugs
2.1.1 Gram-Positive and Gram-Negative Infections
2.1.2 Treating Bacterial Infections
2.2 The Antibacterial Drugs Market 2011
2.2.1 Leading Classes of Antibacterial Drug
2.2.1.1 Cephalosporins
2.2.1.2 Penicillins
2.2.1.3 Fluoroquinolones
2.2.1.4 Macrolides
2.2.1.5 Carbapenems
2.3 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-2022
2.3.1 Market Drivers 2012-2022
2.3.2 Market Restraints 2012-2022
2.4 Leading Antibacterial Drug Manufacturers in 2011
2.4.1 Company Comparison
2.4.1.1 Broad Product Portfolios
2.4.1.2 Regional Focus
2.4.1.3 Future of the Antibacterial Drugs Industry
3. THE LEADING US BIG PHARMA ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022
3.1 Pfizer
3.1.1 A Long History in Antibacterials
3.1.2 Antibacterial Product Portfolio
3.1.2.1 Dalacin (Clindamycin)
3.1.2.2 Sulperazon (Cefoperazone/Sulbactam)
3.1.2.3 Tygacil (Tigecycline)
3.1.2.4 Unasyn (Ampicillin/Sulbactam)
3.1.2.5 Zithromax (Azithromycin)
3.1.2.6 Zosyn (Piperacillin/Tazobactam)
3.1.2.7 Zyvox (Linezolid)
3.1.3 Antibacterial Revenue 2011
3.1.4 Pipeline
3.1.4.1 Pipeline 2007-2010
3.1.4.2 PNU-100480 (Sutezolid)
3.1.5 Pfizer Antibacterials: SWOT Analysis
3.1.6 Antibacterial Revenue Forecast 2012-2022
3.2 Merck & Co.
3.2.1 Antibacterial Product Portfolio
3.2.1.1 Avelox (Moxifloxacin)
3.2.1.2 Invanz (Ertapenem)
3.2.1.3 Primaxin (Imipenem/Cilastatin)
3.2.2 Antibacterial Revenue 2011
3.2.3 Recent Licensing Deals
3.2.4 Pipeline
3.2.4.1 MK-3415A
3.2.4.2 MK-7655
3.2.5 Merck Antibacterials: SWOT Analysis
3.2.6 Antibacterial Revenue Forecast 2012-2022
3.3 J&J
3.3.1 Antibacterial Product Portfolio
3.3.1.1 Doribax (Doripenem)
3.3.1.2 Levaquin (Levofloxacin)
3.3.2 Antibacterial Revenue 2011
3.3.2.1 Patent Challenges
3.3.3 Decreasing Investment in Antibacterials
3.3.4 Pipeline: TMC207
3.3.5 J&J Antibacterials: SWOT Analysis
3.3.6 Antibacterial Revenue Forecast 2012-2022
3.4 Abbott Laboratories
3.4.1 Antibacterial Product Portfolio
3.4.1.1 Biaxin (Clarithromycin)
3.4.2 Antibacterial Revenue 2011
3.4.3 Abbott Antibacterials: SWOT Analysis
3.4.4 Antibacterial Revenue Forecast 2012-2022
4. THE LEADING EUROPEAN BIG PHARMA ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022
4.1 GSK
4.1.1 Antibacterial Product Portfolio
4.1.1.1 Augmentin (Amoxicillin/Clavulanate)
4.1.1.2 Bactroban (Mupirocin)
4.1.1.3 Duac (Clindamycin/Benzoyl Peroxide)
4.1.1.4 Fortum (Ceftazidime)
4.1.1.5 Zinnat (Cefuroxime)
4.1.2 Antibacterial Revenue 2011
4.1.3 Antibacterials in the US
4.1.4 Pipeline
4.1.4.1 GSK2251052
4.1.4.2 GSK1322322
4.1.5 GSK Antibacterials: SWOT Analysis
4.1.6 Antibacterial Revenue Forecast 2012-2022
4.2 Novartis
4.2.1 Antibacterial Product Portfolio
4.2.1.1 Ciprodex (Ciprofloxacin/Dexamethasone)
4.2.1.2 Cubicin (Daptomycin)
4.2.1.3 Moxeza (Moxifloxacin)
4.2.1.4 TOBI Podhaler (Tobramycin Inhalation Powder)
4.2.1.5 Vigamox (Moxifloxacin)
4.2.2 Antibacterial Revenue 2011
4.2.3 Entering and Exiting Licensing Agreements
4.2.4 Pipeline
4.2.4.1 Finafloxacin
4.2.4.2 LFF571
4.2.5 Novartis Antibacterials: SWOT Analysis
4.2.6 Antibacterial Revenue Forecast 2012-2022
4.3 Bayer
4.3.1 Antibacterial Product Portfolio
4.3.1.1 Avelox (Moxifloxacin)
4.3.1.2 Cipro (Ciprofloxacin)
4.3.2 Antibacterial Revenue 2011
4.3.3 Avelox Patent Challenges
4.3.4 Bayer and Trius Therapeutics
4.3.5 Pipeline
4.3.5.1 Ciprofloxacin Inhale
4.3.5.2 Amikacin Inhale
4.3.6 Bayer Antibacterials: SWOT Analysis
4.3.7 Antibacterial Revenue Forecast 2012-2022
4.4 AstraZeneca
4.4.1 Antibacterial Product Portfolio
4.4.1.1 Cubicin (Daptomycin)
4.4.1.2 Merrem (Meropenem)
4.4.1.3 Zinforo (Ceftaroline)
4.4.2 Antibacterial Revenue 2011
4.4.3 AstraZeneca Acquires Novexel
4.4.4 Pipeline
4.4.4.1 CAZ-AVI
4.4.4.2 CEF104
4.4.4.3 NXL103
4.4.4.4 AZD5847
4.4.5 AstraZeneca Antibacterials: SWOT Analysis
4.4.6 Antibacterial Revenue Forecast 2012-2022
4.5 Roche
4.5.1 Antibacterial Product Portfolio
4.5.1.1 Rocephin (Ceftriaxone)
4.5.2 Antibacterial Revenue 2011
4.5.3 Roche Antibacterials: SWOT Analysis
4.5.4 Antibacterial Revenue Forecast 2012-2022
5. THE LEADING JAPANESE ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022
5.1 Daiichi Sankyo
5.1.1 Antibacterial Product Portfolio
5.1.1.1 Cravit (Levofloxacin)
5.1.2 Antibacterial Revenue 2011
5.1.3 Lifecycle Management
5.1.4 Pipeline
5.1.5 Daiichi Sankyo Antibacterials: SWOT Analysis
5.1.6 Antibacterial Revenue Forecast 2012-2022
5.2 Shionogi & Co
5.2.1 Antibacterial Product Portfolio
5.2.1.1 Finibax (Doripenem)
5.2.1.2 Flomox (Cefcapene)
5.2.1.3 Shionogi Acquires Victory Pharma's Portfolio
5.2.2 Antibacterial Revenue 2011
5.2.3 Lifecycle Management
5.2.4 Patent Challenges
5.2.5 Pipeline
5.2.5.1 S-649266
5.2.6 Shionogi Antibacterials: SWOT Analysis
5.2.7 Antibacterial Revenue Forecast 2012-2022
5.3 Meiji Seika Pharma
5.3.1 Antibacterial Product Portfolio
5.3.1.1 Meiact (Cefditoren)
5.3.2 Antibacterial Revenue 2011
5.3.3 Generic Competition
5.3.4 ME1071
5.3.5 Meiji Seika Pharma Antibacterials: SWOT Analysis
5.3.6 Antibacterial Revenue Forecast 2012-2022
5.4 Astellas Pharma
5.4.1 Antibacterial Product Portfolio
5.4.1.1 Cefzon (Cefdinir)
5.4.1.2 Geninax (Garenoxacin)
5.4.2 Antibacterial Revenue 2011
5.4.3 Astellas and Optimer Pharmaceuticals
5.4.4 Astellas and Theravance
5.4.5 Astellas Pharma Antibacterials: SWOT Analysis
5.4.6 Antibacterial Revenue Forecast 2012-2022
5.5 Dainippon Sumitomo Pharma
5.5.1 Meropen (Meropenem)
5.5.2 Antibacterial Revenue 2011
5.5.3 Licensing Deals
5.5.4 Pipeline
5.5.4.1 DSP-5990
5.5.5 Dainippon Sumitomo Antibacterials: SWOT Analysis
5.5.6 Antibacterial Revenue Forecast 2012-2022
6. THE LEADING SPECIALIST ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022
6.1 Cubist Pharmaceuticals
6.1.1 Antibacterial Product Portfolio
6.1.1.1 Cubicin (Daptomycin)
6.1.2 Antibacterial Revenue 2011
6.1.3 Lifecycle Management
6.1.4 Patent Challenges
6.1.5 Pipeline
6.1.5.1 CXA-201
6.1.5.2 CB-315
6.1.6 Cubist Antibacterials: SWOT Analysis
6.1.7 Antibacterial Revenue Forecast 2012-2022
6.2 Medicis
6.2.1 Antibacterial Product Portfolio
6.2.1.1 Solodyn (Minocycline)
6.2.1.2 Ziana (Clindamycin/Tretinoin)
6.2.2 Antibacterial Revenue 2011
6.2.3 Patent Extensions and Challenges
6.2.4 Pipeline
6.2.4.1 GW05
6.2.5 Medicis Antibacterials: SWOT Analysis
6.2.6 Antibacterial Revenue Forecast 2012-2022
6.3 Salix Pharmaceuticals
6.3.1 Xifaxan (Rifamixin)
6.3.2 Antibacterial Revenue 2011
6.3.3 Expanding Approved Indications
6.3.4 Salix Pharmaceuticals Antibacterials: SWOT Analysis
6.3.5 Antibacterial Revenue Forecast 2012-2022
6.4 ViroPharma
6.4.1 Vancocin (Vancomycin)
6.4.2 Antibacterial Revenue 2011
6.4.3 Generic Competition
6.4.4 Pipeline: VP20621
6.4.5 ViroPharma Antibacterials: SWOT Analysis
6.4.6 Antibacterial Revenue Forecast 2012-2022
6.5 Warner Chilcott
6.5.1 Doryx (Doxycycline)
6.5.2 Antibacterial Revenue 2011
6.5.3 Patent Challenges
6.5.4 Pipeline
6.5.5 Warner Chilcott Antibacterials: SWOT Analysis
6.5.6 Antibacterial Revenue Forecast 2012-2022
6.6 Allergan
6.6.1 Antibacterial Product Portfolio
6.6.1.1 Zymar (Gatifloxacin)
6.6.1.2 Zymaxid (Gatifloxacin)
6.6.2 Antibacterial Revenue 2011
6.6.3 Patent Challenges
6.6.4 Allergan Antibacterials: SWOT Analysis
6.6.5 Antibacterial Revenue Forecast 2012-2022
7. EMERGING ANTIBACTERIAL MANUFACTURERS
7.1 Pipeline Companies 2012
7.2 Durata Therapeutics
7.2.1 Future Outlook
7.3 Optimer Pharmaceuticals
7.3.1 Future Outlook
7.4 Rib-X Pharmaceuticals
7.4.1 Future Outlook
7.5 Trius Therapeutics
7.5.1 Future Outlook
8. CONCLUSIONS
8.1 Big Pharma Dominated the Antibacterials Market in 2011
8.2 The Rise of Generics
8.3 Small Companies Can Have a Big Impact on the Industry and Market to 2022
1.1 Leading Antibacterial Drug Manufacturers: Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.4.1 Drugs Considered for this Report
1.4.1.1 Ophthalmic and Dermatologic Antibacterials
1.4.2 The Chinese Antibacterial Drugs Market
1.5 Terminology Used in this Report
2. AN INTRODUCTION TO THE ANTIBACTERIAL DRUGS MARKET
2.1 Bacterial Infections and Antibacterial Drugs
2.1.1 Gram-Positive and Gram-Negative Infections
2.1.2 Treating Bacterial Infections
2.2 The Antibacterial Drugs Market 2011
2.2.1 Leading Classes of Antibacterial Drug
2.2.1.1 Cephalosporins
2.2.1.2 Penicillins
2.2.1.3 Fluoroquinolones
2.2.1.4 Macrolides
2.2.1.5 Carbapenems
2.3 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-2022
2.3.1 Market Drivers 2012-2022
2.3.2 Market Restraints 2012-2022
2.4 Leading Antibacterial Drug Manufacturers in 2011
2.4.1 Company Comparison
2.4.1.1 Broad Product Portfolios
2.4.1.2 Regional Focus
2.4.1.3 Future of the Antibacterial Drugs Industry
3. THE LEADING US BIG PHARMA ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022
3.1 Pfizer
3.1.1 A Long History in Antibacterials
3.1.2 Antibacterial Product Portfolio
3.1.2.1 Dalacin (Clindamycin)
3.1.2.2 Sulperazon (Cefoperazone/Sulbactam)
3.1.2.3 Tygacil (Tigecycline)
3.1.2.4 Unasyn (Ampicillin/Sulbactam)
3.1.2.5 Zithromax (Azithromycin)
3.1.2.6 Zosyn (Piperacillin/Tazobactam)
3.1.2.7 Zyvox (Linezolid)
3.1.3 Antibacterial Revenue 2011
3.1.4 Pipeline
3.1.4.1 Pipeline 2007-2010
3.1.4.2 PNU-100480 (Sutezolid)
3.1.5 Pfizer Antibacterials: SWOT Analysis
3.1.6 Antibacterial Revenue Forecast 2012-2022
3.2 Merck & Co.
3.2.1 Antibacterial Product Portfolio
3.2.1.1 Avelox (Moxifloxacin)
3.2.1.2 Invanz (Ertapenem)
3.2.1.3 Primaxin (Imipenem/Cilastatin)
3.2.2 Antibacterial Revenue 2011
3.2.3 Recent Licensing Deals
3.2.4 Pipeline
3.2.4.1 MK-3415A
3.2.4.2 MK-7655
3.2.5 Merck Antibacterials: SWOT Analysis
3.2.6 Antibacterial Revenue Forecast 2012-2022
3.3 J&J
3.3.1 Antibacterial Product Portfolio
3.3.1.1 Doribax (Doripenem)
3.3.1.2 Levaquin (Levofloxacin)
3.3.2 Antibacterial Revenue 2011
3.3.2.1 Patent Challenges
3.3.3 Decreasing Investment in Antibacterials
3.3.4 Pipeline: TMC207
3.3.5 J&J Antibacterials: SWOT Analysis
3.3.6 Antibacterial Revenue Forecast 2012-2022
3.4 Abbott Laboratories
3.4.1 Antibacterial Product Portfolio
3.4.1.1 Biaxin (Clarithromycin)
3.4.2 Antibacterial Revenue 2011
3.4.3 Abbott Antibacterials: SWOT Analysis
3.4.4 Antibacterial Revenue Forecast 2012-2022
4. THE LEADING EUROPEAN BIG PHARMA ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022
4.1 GSK
4.1.1 Antibacterial Product Portfolio
4.1.1.1 Augmentin (Amoxicillin/Clavulanate)
4.1.1.2 Bactroban (Mupirocin)
4.1.1.3 Duac (Clindamycin/Benzoyl Peroxide)
4.1.1.4 Fortum (Ceftazidime)
4.1.1.5 Zinnat (Cefuroxime)
4.1.2 Antibacterial Revenue 2011
4.1.3 Antibacterials in the US
4.1.4 Pipeline
4.1.4.1 GSK2251052
4.1.4.2 GSK1322322
4.1.5 GSK Antibacterials: SWOT Analysis
4.1.6 Antibacterial Revenue Forecast 2012-2022
4.2 Novartis
4.2.1 Antibacterial Product Portfolio
4.2.1.1 Ciprodex (Ciprofloxacin/Dexamethasone)
4.2.1.2 Cubicin (Daptomycin)
4.2.1.3 Moxeza (Moxifloxacin)
4.2.1.4 TOBI Podhaler (Tobramycin Inhalation Powder)
4.2.1.5 Vigamox (Moxifloxacin)
4.2.2 Antibacterial Revenue 2011
4.2.3 Entering and Exiting Licensing Agreements
4.2.4 Pipeline
4.2.4.1 Finafloxacin
4.2.4.2 LFF571
4.2.5 Novartis Antibacterials: SWOT Analysis
4.2.6 Antibacterial Revenue Forecast 2012-2022
4.3 Bayer
4.3.1 Antibacterial Product Portfolio
4.3.1.1 Avelox (Moxifloxacin)
4.3.1.2 Cipro (Ciprofloxacin)
4.3.2 Antibacterial Revenue 2011
4.3.3 Avelox Patent Challenges
4.3.4 Bayer and Trius Therapeutics
4.3.5 Pipeline
4.3.5.1 Ciprofloxacin Inhale
4.3.5.2 Amikacin Inhale
4.3.6 Bayer Antibacterials: SWOT Analysis
4.3.7 Antibacterial Revenue Forecast 2012-2022
4.4 AstraZeneca
4.4.1 Antibacterial Product Portfolio
4.4.1.1 Cubicin (Daptomycin)
4.4.1.2 Merrem (Meropenem)
4.4.1.3 Zinforo (Ceftaroline)
4.4.2 Antibacterial Revenue 2011
4.4.3 AstraZeneca Acquires Novexel
4.4.4 Pipeline
4.4.4.1 CAZ-AVI
4.4.4.2 CEF104
4.4.4.3 NXL103
4.4.4.4 AZD5847
4.4.5 AstraZeneca Antibacterials: SWOT Analysis
4.4.6 Antibacterial Revenue Forecast 2012-2022
4.5 Roche
4.5.1 Antibacterial Product Portfolio
4.5.1.1 Rocephin (Ceftriaxone)
4.5.2 Antibacterial Revenue 2011
4.5.3 Roche Antibacterials: SWOT Analysis
4.5.4 Antibacterial Revenue Forecast 2012-2022
5. THE LEADING JAPANESE ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022
5.1 Daiichi Sankyo
5.1.1 Antibacterial Product Portfolio
5.1.1.1 Cravit (Levofloxacin)
5.1.2 Antibacterial Revenue 2011
5.1.3 Lifecycle Management
5.1.4 Pipeline
5.1.5 Daiichi Sankyo Antibacterials: SWOT Analysis
5.1.6 Antibacterial Revenue Forecast 2012-2022
5.2 Shionogi & Co
5.2.1 Antibacterial Product Portfolio
5.2.1.1 Finibax (Doripenem)
5.2.1.2 Flomox (Cefcapene)
5.2.1.3 Shionogi Acquires Victory Pharma's Portfolio
5.2.2 Antibacterial Revenue 2011
5.2.3 Lifecycle Management
5.2.4 Patent Challenges
5.2.5 Pipeline
5.2.5.1 S-649266
5.2.6 Shionogi Antibacterials: SWOT Analysis
5.2.7 Antibacterial Revenue Forecast 2012-2022
5.3 Meiji Seika Pharma
5.3.1 Antibacterial Product Portfolio
5.3.1.1 Meiact (Cefditoren)
5.3.2 Antibacterial Revenue 2011
5.3.3 Generic Competition
5.3.4 ME1071
5.3.5 Meiji Seika Pharma Antibacterials: SWOT Analysis
5.3.6 Antibacterial Revenue Forecast 2012-2022
5.4 Astellas Pharma
5.4.1 Antibacterial Product Portfolio
5.4.1.1 Cefzon (Cefdinir)
5.4.1.2 Geninax (Garenoxacin)
5.4.2 Antibacterial Revenue 2011
5.4.3 Astellas and Optimer Pharmaceuticals
5.4.4 Astellas and Theravance
5.4.5 Astellas Pharma Antibacterials: SWOT Analysis
5.4.6 Antibacterial Revenue Forecast 2012-2022
5.5 Dainippon Sumitomo Pharma
5.5.1 Meropen (Meropenem)
5.5.2 Antibacterial Revenue 2011
5.5.3 Licensing Deals
5.5.4 Pipeline
5.5.4.1 DSP-5990
5.5.5 Dainippon Sumitomo Antibacterials: SWOT Analysis
5.5.6 Antibacterial Revenue Forecast 2012-2022
6. THE LEADING SPECIALIST ANTIBACTERIAL DRUG MANUFACTURERS 2012-2022
6.1 Cubist Pharmaceuticals
6.1.1 Antibacterial Product Portfolio
6.1.1.1 Cubicin (Daptomycin)
6.1.2 Antibacterial Revenue 2011
6.1.3 Lifecycle Management
6.1.4 Patent Challenges
6.1.5 Pipeline
6.1.5.1 CXA-201
6.1.5.2 CB-315
6.1.6 Cubist Antibacterials: SWOT Analysis
6.1.7 Antibacterial Revenue Forecast 2012-2022
6.2 Medicis
6.2.1 Antibacterial Product Portfolio
6.2.1.1 Solodyn (Minocycline)
6.2.1.2 Ziana (Clindamycin/Tretinoin)
6.2.2 Antibacterial Revenue 2011
6.2.3 Patent Extensions and Challenges
6.2.4 Pipeline
6.2.4.1 GW05
6.2.5 Medicis Antibacterials: SWOT Analysis
6.2.6 Antibacterial Revenue Forecast 2012-2022
6.3 Salix Pharmaceuticals
6.3.1 Xifaxan (Rifamixin)
6.3.2 Antibacterial Revenue 2011
6.3.3 Expanding Approved Indications
6.3.4 Salix Pharmaceuticals Antibacterials: SWOT Analysis
6.3.5 Antibacterial Revenue Forecast 2012-2022
6.4 ViroPharma
6.4.1 Vancocin (Vancomycin)
6.4.2 Antibacterial Revenue 2011
6.4.3 Generic Competition
6.4.4 Pipeline: VP20621
6.4.5 ViroPharma Antibacterials: SWOT Analysis
6.4.6 Antibacterial Revenue Forecast 2012-2022
6.5 Warner Chilcott
6.5.1 Doryx (Doxycycline)
6.5.2 Antibacterial Revenue 2011
6.5.3 Patent Challenges
6.5.4 Pipeline
6.5.5 Warner Chilcott Antibacterials: SWOT Analysis
6.5.6 Antibacterial Revenue Forecast 2012-2022
6.6 Allergan
6.6.1 Antibacterial Product Portfolio
6.6.1.1 Zymar (Gatifloxacin)
6.6.1.2 Zymaxid (Gatifloxacin)
6.6.2 Antibacterial Revenue 2011
6.6.3 Patent Challenges
6.6.4 Allergan Antibacterials: SWOT Analysis
6.6.5 Antibacterial Revenue Forecast 2012-2022
7. EMERGING ANTIBACTERIAL MANUFACTURERS
7.1 Pipeline Companies 2012
7.2 Durata Therapeutics
7.2.1 Future Outlook
7.3 Optimer Pharmaceuticals
7.3.1 Future Outlook
7.4 Rib-X Pharmaceuticals
7.4.1 Future Outlook
7.5 Trius Therapeutics
7.5.1 Future Outlook
8. CONCLUSIONS
8.1 Big Pharma Dominated the Antibacterials Market in 2011
8.2 The Rise of Generics
8.3 Small Companies Can Have a Big Impact on the Industry and Market to 2022
LIST OF TABLES
Table 1.1 Currency Exchange Rates, 2011
Table 1.2 Common Abbreviations Used in this Report
Table 2.1 Classification of Common Infection-Causing Bacteria
Table 2.2 Antibacterial Drugs Market by Class, 2010-2011
Table 2.3 Selected Classes of Antibacterial Drug and their Mechanism of Action
Table 2.4 Cephalosporins: Role in the Antibacterial Drugs Market, 2011
Table 2.5 Penicillins: Role in the Antibacterial Drugs Market, 2011
Table 2.6 Fluoroquinolones: Role in the Antibacterial Drugs Market, 2011
Table 2.7 Macrolides: Role in the Antibacterial Drugs Market, 2011
Table 2.8 Carbapenems: Role in the Antibacterial Drugs Market, 2011
Table 2.9 Antibacterial Drugs: Overall World Market and Submarket Forecasting, 2011, 2016 & 2022
Table 2.10 Top 20 Antibacterial Manufacturers by Revenue, 2011
Table 2.11 Antibacterial Revenue as a Share of Pharmaceutical Revenue, 2011
Table 3.1 Pfizer: Key Facts, 2012
Table 3.2 Pfizer: Antibacterial Revenue, 2009-2011
Table 3.3 Pfizer: Antibacterial SWOT Analysis, 2012-2022
Table 3.4 Pfizer: Antibacterial Revenue Forecast, 2011-2022
Table 3.5 Merck & Co: Key Facts, 2012
Table 3.6 Merck & Co: Antibacterial Revenue, 2009-2011
Table 3.7 Merck & Co: Antibacterial SWOT Analysis, 2012-2022
Table 3.8 Merck & Co: Antibacterial Revenue Forecast, 2011-2022
Table 3.9 J&J: Key Facts, 2012
Table 3.10 J&J: Antibacterial Revenue, 2009-2011
Table 3.11 J&J: Antibacterial SWOT Analysis, 2012-2022
Table 3.12 J&J: Antibacterial Revenue Forecast, 2011-2022
Table 3.13 Abbott: Key Facts, 2012
Table 3.14 Abbott: Antibacterial SWOT Analysis, 2012-2022
Table 3.15 Abbott: Antibacterial Revenue Forecast, 2011-2022
Table 4.1 GSK: Key Facts, 2012
Table 4.2 GSK: Antibacterial Revenue, 2010-2011
Table 4.3 Augmentin, Revenue by Region, 2011
Table 4.4 GSK: Antibacterial Drug Pipeline, 2012
Table 4.5 GSK: Antibacterial SWOT Analysis, 2012-2022
Table 4.6 GSK: Antibacterial Revenue Forecast, 2011-2022
Table 4.7 Novartis: Key Facts, 2012
Table 4.8 Novartis: Antibacterial Revenue, 2009-2011
Table 4.9 Novartis: Antibacterial SWOT Analysis, 2012-2022
Table 4.10 Novartis: Antibacterial Revenue Forecast, 2011-2022
Table 4.11 Bayer: Key Facts, 2012
Table 4.12 Bayer: Antibacterial Revenue, 2009-2011
Table 4.13 Avelox: Patent Expiries by Country, 2013-2015
Table 4.14 Bayer: Antibacterial SWOT Analysis, 2012-2022
Table 4.15 Bayer: Antibacterial Revenue Forecast, 2011-2022
Table 4.16 AstraZeneca: Key Facts, 2012
Table 4.17 AstraZeneca: Antibacterial Revenue, 2008-2011
Table 4.18 AstraZeneca: Antibacterial SWOT Analysis, 2012-2022
Table 4.19 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022
Table 4.20 Roche: Key Facts, 2012
Table 4.21 Roche: Antibacterial Revenue, Q1-Q4 2011
Table 4.22 Roche: Antibacterial Revenue by Region, Q1 2012
Table 4.23 Roche: Antibacterial SWOT Analysis, 2012-2022
Table 4.24 Roche: Antibacterial Revenue Forecast, 2011-2022
Table 5.1 Daiichi Sankyo: Key Facts, 2012
Table 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011
Table 5.3 Daiichi Sankyo: Antibacterial SWOT Analysis, 2012-2022
Table 5.4 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022
Table 5.5 Shionogi: Key Facts, 2012
Table 5.6 Shionogi: Antibacterial SWOT Analysis, 2012-2022
Table 5.7 Shionogi: Antibacterial Revenue Forecast, 2011-2022
Table 5.8 Meiji Seika Pharma: Key Facts, 2012
Table 5.9 Meiji Seika Pharma: Antibacterial SWOT Analysis, 2012-2022
Table 5.10 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022
Table 5.11 Astellas Pharma: Key Facts, 2012
Table 5.12 Astellas Pharma: Leading Antibacterial Drug Revenue, FY 2007-2011
Table 5.13 Astellas Pharma: Antibacterial SWOT Analysis, 2012-2022
Table 5.14 Astellas Pharma: Antibacterial Revenue Forecast, 2011-2022
Table 5.15 Dainippon Sumitomo: Key Facts, 2012
Table 5.16 Dainippon Sumitomo: Antibacterial Revenue, FY 2009-2011
Table 5.17 Dainippon Sumitomo: Antibacterial SWOT Analysis, 2012-2022
Table 5.18 Dainippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022
Table 6.1 Cubist Pharmaceuticals: Key Facts, 2012
Table 6.2 Cubist: Antibacterial Revenue, 2008-2011
Table 6.3 Cubicin: International Revenue Payments, 2008-2011
Table 6.4 Cubist: Antibacterial SWOT Analysis, 2012-2022
Table 6.5 Cubist: Antibacterial Revenue Forecast, 2011-2022
Table 6.6 Medicis: Key Facts, 2012
Table 6.7 Medicis: Antibacterial Revenue, 2009-2011
Table 6.8 Medicis: Antibacterial SWOT Analysis, 2012-2022
Table 6.9 Medicis: Antibacterial Revenue Forecast, 2011-2022
Table 6.10 Salix Pharmaceuticals: Key Facts, 2012
Table 6.11 Salix: Antibacterial Revenue, 2009-2011
Table 6.12 Salix: Antibacterial SWOT Analysis, 2012-2022
Table 6.13 Salix: Antibacterial Revenue Forecast, 2011-2022
Table 6.14 ViroPharma: Key Facts, 2012
Table 6.15 ViroPharma: Antibacterial Revenue, 2009-2011
Table 6.16 ViroPharma: Antibacterial SWOT Analysis, 2012-2022
Table 6.17 ViroPharma: Antibacterial Revenue Forecast, 2011-2022
Table 6.18 Warner Chilcott: Key Facts, 2012
Table 6.19 Warner Chilcott: Antibacterial SWOT Analysis, 2012-2022
Table 6.20 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022
Table 6.21 Allergan: Key Facts, 2012
Table 6.22 Allergan: Antibacterial SWOT Analysis, 2012-2022
Table 6.23 Allergan: Antibacterial Revenue Forecast, 2011-2022
Table 7.1 Emerging Companies in the Antibacterial Drugs Market, 2012
Table 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011
Table 1.1 Currency Exchange Rates, 2011
Table 1.2 Common Abbreviations Used in this Report
Table 2.1 Classification of Common Infection-Causing Bacteria
Table 2.2 Antibacterial Drugs Market by Class, 2010-2011
Table 2.3 Selected Classes of Antibacterial Drug and their Mechanism of Action
Table 2.4 Cephalosporins: Role in the Antibacterial Drugs Market, 2011
Table 2.5 Penicillins: Role in the Antibacterial Drugs Market, 2011
Table 2.6 Fluoroquinolones: Role in the Antibacterial Drugs Market, 2011
Table 2.7 Macrolides: Role in the Antibacterial Drugs Market, 2011
Table 2.8 Carbapenems: Role in the Antibacterial Drugs Market, 2011
Table 2.9 Antibacterial Drugs: Overall World Market and Submarket Forecasting, 2011, 2016 & 2022
Table 2.10 Top 20 Antibacterial Manufacturers by Revenue, 2011
Table 2.11 Antibacterial Revenue as a Share of Pharmaceutical Revenue, 2011
Table 3.1 Pfizer: Key Facts, 2012
Table 3.2 Pfizer: Antibacterial Revenue, 2009-2011
Table 3.3 Pfizer: Antibacterial SWOT Analysis, 2012-2022
Table 3.4 Pfizer: Antibacterial Revenue Forecast, 2011-2022
Table 3.5 Merck & Co: Key Facts, 2012
Table 3.6 Merck & Co: Antibacterial Revenue, 2009-2011
Table 3.7 Merck & Co: Antibacterial SWOT Analysis, 2012-2022
Table 3.8 Merck & Co: Antibacterial Revenue Forecast, 2011-2022
Table 3.9 J&J: Key Facts, 2012
Table 3.10 J&J: Antibacterial Revenue, 2009-2011
Table 3.11 J&J: Antibacterial SWOT Analysis, 2012-2022
Table 3.12 J&J: Antibacterial Revenue Forecast, 2011-2022
Table 3.13 Abbott: Key Facts, 2012
Table 3.14 Abbott: Antibacterial SWOT Analysis, 2012-2022
Table 3.15 Abbott: Antibacterial Revenue Forecast, 2011-2022
Table 4.1 GSK: Key Facts, 2012
Table 4.2 GSK: Antibacterial Revenue, 2010-2011
Table 4.3 Augmentin, Revenue by Region, 2011
Table 4.4 GSK: Antibacterial Drug Pipeline, 2012
Table 4.5 GSK: Antibacterial SWOT Analysis, 2012-2022
Table 4.6 GSK: Antibacterial Revenue Forecast, 2011-2022
Table 4.7 Novartis: Key Facts, 2012
Table 4.8 Novartis: Antibacterial Revenue, 2009-2011
Table 4.9 Novartis: Antibacterial SWOT Analysis, 2012-2022
Table 4.10 Novartis: Antibacterial Revenue Forecast, 2011-2022
Table 4.11 Bayer: Key Facts, 2012
Table 4.12 Bayer: Antibacterial Revenue, 2009-2011
Table 4.13 Avelox: Patent Expiries by Country, 2013-2015
Table 4.14 Bayer: Antibacterial SWOT Analysis, 2012-2022
Table 4.15 Bayer: Antibacterial Revenue Forecast, 2011-2022
Table 4.16 AstraZeneca: Key Facts, 2012
Table 4.17 AstraZeneca: Antibacterial Revenue, 2008-2011
Table 4.18 AstraZeneca: Antibacterial SWOT Analysis, 2012-2022
Table 4.19 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022
Table 4.20 Roche: Key Facts, 2012
Table 4.21 Roche: Antibacterial Revenue, Q1-Q4 2011
Table 4.22 Roche: Antibacterial Revenue by Region, Q1 2012
Table 4.23 Roche: Antibacterial SWOT Analysis, 2012-2022
Table 4.24 Roche: Antibacterial Revenue Forecast, 2011-2022
Table 5.1 Daiichi Sankyo: Key Facts, 2012
Table 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011
Table 5.3 Daiichi Sankyo: Antibacterial SWOT Analysis, 2012-2022
Table 5.4 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022
Table 5.5 Shionogi: Key Facts, 2012
Table 5.6 Shionogi: Antibacterial SWOT Analysis, 2012-2022
Table 5.7 Shionogi: Antibacterial Revenue Forecast, 2011-2022
Table 5.8 Meiji Seika Pharma: Key Facts, 2012
Table 5.9 Meiji Seika Pharma: Antibacterial SWOT Analysis, 2012-2022
Table 5.10 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022
Table 5.11 Astellas Pharma: Key Facts, 2012
Table 5.12 Astellas Pharma: Leading Antibacterial Drug Revenue, FY 2007-2011
Table 5.13 Astellas Pharma: Antibacterial SWOT Analysis, 2012-2022
Table 5.14 Astellas Pharma: Antibacterial Revenue Forecast, 2011-2022
Table 5.15 Dainippon Sumitomo: Key Facts, 2012
Table 5.16 Dainippon Sumitomo: Antibacterial Revenue, FY 2009-2011
Table 5.17 Dainippon Sumitomo: Antibacterial SWOT Analysis, 2012-2022
Table 5.18 Dainippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022
Table 6.1 Cubist Pharmaceuticals: Key Facts, 2012
Table 6.2 Cubist: Antibacterial Revenue, 2008-2011
Table 6.3 Cubicin: International Revenue Payments, 2008-2011
Table 6.4 Cubist: Antibacterial SWOT Analysis, 2012-2022
Table 6.5 Cubist: Antibacterial Revenue Forecast, 2011-2022
Table 6.6 Medicis: Key Facts, 2012
Table 6.7 Medicis: Antibacterial Revenue, 2009-2011
Table 6.8 Medicis: Antibacterial SWOT Analysis, 2012-2022
Table 6.9 Medicis: Antibacterial Revenue Forecast, 2011-2022
Table 6.10 Salix Pharmaceuticals: Key Facts, 2012
Table 6.11 Salix: Antibacterial Revenue, 2009-2011
Table 6.12 Salix: Antibacterial SWOT Analysis, 2012-2022
Table 6.13 Salix: Antibacterial Revenue Forecast, 2011-2022
Table 6.14 ViroPharma: Key Facts, 2012
Table 6.15 ViroPharma: Antibacterial Revenue, 2009-2011
Table 6.16 ViroPharma: Antibacterial SWOT Analysis, 2012-2022
Table 6.17 ViroPharma: Antibacterial Revenue Forecast, 2011-2022
Table 6.18 Warner Chilcott: Key Facts, 2012
Table 6.19 Warner Chilcott: Antibacterial SWOT Analysis, 2012-2022
Table 6.20 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022
Table 6.21 Allergan: Key Facts, 2012
Table 6.22 Allergan: Antibacterial SWOT Analysis, 2012-2022
Table 6.23 Allergan: Antibacterial Revenue Forecast, 2011-2022
Table 7.1 Emerging Companies in the Antibacterial Drugs Market, 2012
Table 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011
LIST OF FIGURES
Figure 2.1 Antibacterial Drugs Market by Class, 2010-2011
Figure 2.2 Antibacterial Drugs: Overall Market Forecast, 2011, 2016 & 2022
Figure 2.3 Antibacterial Drugs Market: Drivers and Restraints, 2012-2022
Figure 2.4 Top 20 Antibacterial Manufacturers by Revenue, 2011
Figure 2.5 Antibacterial Drug Market Entry, 1935-2004
Figure 3.1 Pfizer: Antibacterial Market History, 1944-2009
Figure 3.2 Pfizer: Antibacterial Revenue Shares, 2011
Figure 3.3 Pfizer: Antibacterial Revenue Forecast, 2011-2022
Figure 3.4 Pfizer: Antibacterial Market Share, 2011-2022
Figure 3.5 Merck & Co: Antibacterial Revenue, 2009-2011
Figure 3.6 Merck & Co: Antibacterial Revenue Forecast, 2011-2022
Figure 3.7 Merck & Co: Antibacterial Market Share, 2011-2022
Figure 3.8 J&J: Antibacterial Revenue, 2009-2011
Figure 3.9 J&J: Antibacterial Revenue Forecast, 2011-2022
Figure 3.10 J&J: Antibacterial Market Share, 2011-2022
Figure 3.11 Abbott: Antibacterial Revenue Forecast, 2011-2022
Figure 3.12 Abbott: Antibacterial Market Share, 2011-2022
Figure 4.1 GSK: Antibacterial Revenue Shares, 2011
Figure 4.2 Augmentin, Revenue Shares by Region, 2011
Figure 4.3 GSK: Antibacterial Revenue Forecast, 2011-2022
Figure 4.4 GSK: Antibacterial Market Share, 2011-2022
Figure 4.5 Novartis: Antibacterial Revenue Shares, 2011
Figure 4.6 Novartis: Antibacterial Revenue Forecast, 2011-2022
Figure 4.7 Novartis: Antibacterial Market Share, 2011-2022
Figure 4.8 Bayer: Antibacterial Revenue, 2009-2011
Figure 4.9 Bayer: Antibacterial Revenue Forecast, 2011-2022
Figure 4.10 Bayer: Antibacterial Market Share, 2011-2022
Figure 4.11 AstraZeneca: Antibacterial Sales Revenue, 2008-2011
Figure 4.12 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022
Figure 4.13 AstraZeneca: Antibacterial Market Share, 2011-2022
Figure 4.14 Roche: Antibacterial Revenue Shares, Q1-Q4 2011
Figure 4.15 Roche: Antibacterial Revenue Shares by Region, Q1 2012
Figure 4.16 Roche: Antibacterial Revenue Forecast, 2011-2022
Figure 4.17 Roche: Antibacterial Market Share, 2011-2022
Figure 5.1 Daiichi Sankyo: Antibacterial Market History, 1937-1993
Figure 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011
Figure 5.3 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022
Figure 5.4 Daiichi Sankyo: Antibacterial Market Share, 2011-2022
Figure 5.5 Shionogi: Antibacterial Revenue Forecast, 2011-2022
Figure 5.6 Shionogi: Antibacterial Market Share, 2011-2022
Figure 5.7 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022
Figure 5.8 Meiji Seika Pharma: Antibacterial Market Share, 2011-2022
Figure 5.9 Astellas Pharma: Leading Antibacterial Drug Revenues, FY 2007-2011
Figure 5.10 Astellas Pharma: Antibacterial Revenue Forecast, 2011-2022
Figure 5.11 Astellas Pharma: Antibacterial Market Share, 2011-2022
Figure 5.12 Dainippon Sumitomo: Antibacterial Revenue, FY 2009-2011
Figure 5.13 Dainippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022
Figure 5.14 Dainippon Sumitomo: Antibacterial Market Share, 2011-2022
Figure 6.1 Cubist: Antibacterial Revenue, 2008-2011
Figure 6.2 Cubicin: International Revenue Payments, 2008-2011
Figure 6.3 Cubist: Antibacterial Market Share, 2011-2022
Figure 6.4 Cubist: Antibacterial Revenue Forecast, 2011-2022
Figure 6.5 Medicis: Antibacterial Revenue, 2009-2011
Figure 6.6 Medicis: Antibacterial Revenue Forecast, 2011-2022
Figure 6.7 Medicis: Antibacterial Market Share, 2011-2022
Figure 6.8 Salix: Antibacterial Revenue, 2009-2011
Figure 6.9 Salix: Antibacterial Revenue Forecast, 2011-2022
Figure 6.10 Salix: Antibacterial Market Share, 2011-2022
Figure 6.11 ViroPharma: Antibacterial Revenue, 2009-2011
Figure 6.12 ViroPharma: Antibacterial Revenue Forecast, 2011-2022
Figure 6.13 ViroPharma: Antibacterial Market Share, 2011-2022
Figure 6.14 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022
Figure 6.15 Warner Chilcott: Antibacterial Market Share, 2011-2022
Figure 6.16 Allergan: Antibacterial Revenue Forecast, 2011-2022
Figure 6.17 Allergan: Antibacterial Market Share, 2011-2022
Figure 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011
COMPANIES LISTED
Abbott Laboratories
Adolor (part of Cubist)
Advanced Life Sciences
AiCuris
Akorn
Alcon Laboratories (a division of Novartis)
Alfa Wassermann
Allergan
Anacor Pharmaceuticals
Apotex
Astellas Pharma
AstraZeneca
Barr Laboratories (part of Teva)
Basilea Pharmaceutica
Bayer
BioRelix
Biovail Laboratories (part of Valeant Pharmaceuticals)
Bristol-Myers Squibb
Calixa Therapeutics (part of Cubist)
Cempra Pharmaceuticals
Chiron (now part of Novartis)
Cornerstone Therapeutics
Cubist Pharmaceuticals
Daiichi Sankyo
Daiichi Sankyo Pharmaceutical (Beijing)
Daiichi Sankyo Pharmaceutical (Shanghai)
Dainippon Pharmaceutical (part of Dainippon Sumitomo)
Dainippon Sumitomo Pharma
DAVA Pharmaceuticals
Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) [US]
Dr Reddy's Laboratories
Durata Therapeutics
Eli Lilly
EMA Committee for Medicinal Products for Human Use (CHMP) [EU]
European Medicines Agency (EMA)
Food and Drug Administration (FDA) [US]
Forest Laboratories
Fujisawa Pharmaceutical (part of Astellas Pharma)
Furiex Pharmaceuticals
Genzyme (part of Sanofi)
Graceway Pharmaceuticals
GSK
Heritage Pharmaceuticals
Hikma Farmaceutica
Hi-Tech Pharmacal
Hospira
Impax Laboratories
Innovative Medicines Initiative [EU]
Itochu Chemical Frontier
Janssen Pharmaceutica (a subsidiary of J&J)
Japan Patent Office (JPO)
Johnson & Johnson (J&J)
Kyorin Pharmaceutical
Lupin
Massachusetts Biologic Laboratories
Mayne Pharma
Medarex (part of Bristol-Myers Squibb)
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Medicis
Medison Pharma
Meiji Holdings (parent company of Meiji Seika Pharma)
Meiji Seika Pharma
Merck & Co.
MerLion Pharmaceuticals
Ministry of Health, Labor and Welfare (MHLW)
Mylan
Mylan Seiyaku (a subsidiary of Mylan)
Nabriva Therapeutics
Nanotherapeutics
National Institute of Allergy and Infectious Diseases (NIAID) [US]
Nektar Therapeutics
NestlŠ¹
NeuTec Pharma (part of Novartis, now closed)
Nichi-Iko Pharmaceutical
Nipro Pharma
Novartis
Novexel (part of AstraZeneca)
Optimer Biotechnology (a subsidiary of Optimer)
Optimer Pharmaceuticals
Ortho-McNeil Pharmaceutical (a subsidiary of J&J)
Paratek Pharmaceuticals
Patent and Trademark Office [US]
Peninsula Pharmaceuticals (part of J&J)
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmacia (part of Pfizer)
Pliva (part of Teva)
Proctor & Gamble (P&G)
Protez Pharmaceuticals (part of Novartis, now closed)
Ranbaxy (part of Daiichi Sankyo)
Rib-X Pharmaceuticals
Roche
Rutgers University [US]
Salix Pharmaceuticals
Sandoz (a division of Novartis)
Sanofi
Sawai Pharmaceutical
Schering-Plough (part of Merck & Co)
Scottish Medicines Consortium (SMC)
Senju Pharmaceutical
Sequella
Shantou Meiji Pharmaceuticals (a subsidiary of Meiji Seika Pharma)
Shionogi & Co
Simcere Pharmaceutical Group
State Food and Drug Administration (SFDA) [China]
Stiefel Laboratories (part of GSK)
Strides Arcolab
Sumitomo Pharmaceutical (part of Dainippon Sumitomo)
Sunovion Pharmaceuticals
TaiGen Biotechnology
Taisho Pharmaceutical
Taiyo Yakuhin (Taiyo Pharmaceutical Industry)
Takeda Pharmaceutical
TB Alliance
Tedec-Meiji Farma (a subsidiary of Meiji Seika Pharma)
Tetraphase Pharmaceuticals
Teva Pharmaceutical Industries
The Medicines Company
Theravance
Tibotec Pharmaceuticals (part of Janssen Pharmaceutica)
Towa Pharmaceutical
Toyama Chemical
Trius Therapeutics
Upjohn (part of Pfizer)
Victory Pharma
Vicuron Pharmaceuticals (part of Durata)
ViroPharma
Wakunaga Pharmaceutical
Warner Chilcott
Warner Lambert (part of Pfizer)
Watson Pharmaceuticals
Women First HealthCare
World Health Organization (WHO)
Wyeth Pharmaceuticals (part of Pfizer)
Yale University [US]
Yamanouchi Pharmaceutical (part of Astellas)
Zuellig Pharma
Figure 2.1 Antibacterial Drugs Market by Class, 2010-2011
Figure 2.2 Antibacterial Drugs: Overall Market Forecast, 2011, 2016 & 2022
Figure 2.3 Antibacterial Drugs Market: Drivers and Restraints, 2012-2022
Figure 2.4 Top 20 Antibacterial Manufacturers by Revenue, 2011
Figure 2.5 Antibacterial Drug Market Entry, 1935-2004
Figure 3.1 Pfizer: Antibacterial Market History, 1944-2009
Figure 3.2 Pfizer: Antibacterial Revenue Shares, 2011
Figure 3.3 Pfizer: Antibacterial Revenue Forecast, 2011-2022
Figure 3.4 Pfizer: Antibacterial Market Share, 2011-2022
Figure 3.5 Merck & Co: Antibacterial Revenue, 2009-2011
Figure 3.6 Merck & Co: Antibacterial Revenue Forecast, 2011-2022
Figure 3.7 Merck & Co: Antibacterial Market Share, 2011-2022
Figure 3.8 J&J: Antibacterial Revenue, 2009-2011
Figure 3.9 J&J: Antibacterial Revenue Forecast, 2011-2022
Figure 3.10 J&J: Antibacterial Market Share, 2011-2022
Figure 3.11 Abbott: Antibacterial Revenue Forecast, 2011-2022
Figure 3.12 Abbott: Antibacterial Market Share, 2011-2022
Figure 4.1 GSK: Antibacterial Revenue Shares, 2011
Figure 4.2 Augmentin, Revenue Shares by Region, 2011
Figure 4.3 GSK: Antibacterial Revenue Forecast, 2011-2022
Figure 4.4 GSK: Antibacterial Market Share, 2011-2022
Figure 4.5 Novartis: Antibacterial Revenue Shares, 2011
Figure 4.6 Novartis: Antibacterial Revenue Forecast, 2011-2022
Figure 4.7 Novartis: Antibacterial Market Share, 2011-2022
Figure 4.8 Bayer: Antibacterial Revenue, 2009-2011
Figure 4.9 Bayer: Antibacterial Revenue Forecast, 2011-2022
Figure 4.10 Bayer: Antibacterial Market Share, 2011-2022
Figure 4.11 AstraZeneca: Antibacterial Sales Revenue, 2008-2011
Figure 4.12 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022
Figure 4.13 AstraZeneca: Antibacterial Market Share, 2011-2022
Figure 4.14 Roche: Antibacterial Revenue Shares, Q1-Q4 2011
Figure 4.15 Roche: Antibacterial Revenue Shares by Region, Q1 2012
Figure 4.16 Roche: Antibacterial Revenue Forecast, 2011-2022
Figure 4.17 Roche: Antibacterial Market Share, 2011-2022
Figure 5.1 Daiichi Sankyo: Antibacterial Market History, 1937-1993
Figure 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011
Figure 5.3 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022
Figure 5.4 Daiichi Sankyo: Antibacterial Market Share, 2011-2022
Figure 5.5 Shionogi: Antibacterial Revenue Forecast, 2011-2022
Figure 5.6 Shionogi: Antibacterial Market Share, 2011-2022
Figure 5.7 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022
Figure 5.8 Meiji Seika Pharma: Antibacterial Market Share, 2011-2022
Figure 5.9 Astellas Pharma: Leading Antibacterial Drug Revenues, FY 2007-2011
Figure 5.10 Astellas Pharma: Antibacterial Revenue Forecast, 2011-2022
Figure 5.11 Astellas Pharma: Antibacterial Market Share, 2011-2022
Figure 5.12 Dainippon Sumitomo: Antibacterial Revenue, FY 2009-2011
Figure 5.13 Dainippon Sumitomo: Antibacterial Revenue Forecast, 2011-2022
Figure 5.14 Dainippon Sumitomo: Antibacterial Market Share, 2011-2022
Figure 6.1 Cubist: Antibacterial Revenue, 2008-2011
Figure 6.2 Cubicin: International Revenue Payments, 2008-2011
Figure 6.3 Cubist: Antibacterial Market Share, 2011-2022
Figure 6.4 Cubist: Antibacterial Revenue Forecast, 2011-2022
Figure 6.5 Medicis: Antibacterial Revenue, 2009-2011
Figure 6.6 Medicis: Antibacterial Revenue Forecast, 2011-2022
Figure 6.7 Medicis: Antibacterial Market Share, 2011-2022
Figure 6.8 Salix: Antibacterial Revenue, 2009-2011
Figure 6.9 Salix: Antibacterial Revenue Forecast, 2011-2022
Figure 6.10 Salix: Antibacterial Market Share, 2011-2022
Figure 6.11 ViroPharma: Antibacterial Revenue, 2009-2011
Figure 6.12 ViroPharma: Antibacterial Revenue Forecast, 2011-2022
Figure 6.13 ViroPharma: Antibacterial Market Share, 2011-2022
Figure 6.14 Warner Chilcott: Antibacterial Revenue Forecast, 2011-2022
Figure 6.15 Warner Chilcott: Antibacterial Market Share, 2011-2022
Figure 6.16 Allergan: Antibacterial Revenue Forecast, 2011-2022
Figure 6.17 Allergan: Antibacterial Market Share, 2011-2022
Figure 8.1 Top 20 Antibacterial Manufacturers by Company Type, 2011
COMPANIES LISTED
Abbott Laboratories
Adolor (part of Cubist)
Advanced Life Sciences
AiCuris
Akorn
Alcon Laboratories (a division of Novartis)
Alfa Wassermann
Allergan
Anacor Pharmaceuticals
Apotex
Astellas Pharma
AstraZeneca
Barr Laboratories (part of Teva)
Basilea Pharmaceutica
Bayer
BioRelix
Biovail Laboratories (part of Valeant Pharmaceuticals)
Bristol-Myers Squibb
Calixa Therapeutics (part of Cubist)
Cempra Pharmaceuticals
Chiron (now part of Novartis)
Cornerstone Therapeutics
Cubist Pharmaceuticals
Daiichi Sankyo
Daiichi Sankyo Pharmaceutical (Beijing)
Daiichi Sankyo Pharmaceutical (Shanghai)
Dainippon Pharmaceutical (part of Dainippon Sumitomo)
Dainippon Sumitomo Pharma
DAVA Pharmaceuticals
Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) [US]
Dr Reddy's Laboratories
Durata Therapeutics
Eli Lilly
EMA Committee for Medicinal Products for Human Use (CHMP) [EU]
European Medicines Agency (EMA)
Food and Drug Administration (FDA) [US]
Forest Laboratories
Fujisawa Pharmaceutical (part of Astellas Pharma)
Furiex Pharmaceuticals
Genzyme (part of Sanofi)
Graceway Pharmaceuticals
GSK
Heritage Pharmaceuticals
Hikma Farmaceutica
Hi-Tech Pharmacal
Hospira
Impax Laboratories
Innovative Medicines Initiative [EU]
Itochu Chemical Frontier
Janssen Pharmaceutica (a subsidiary of J&J)
Japan Patent Office (JPO)
Johnson & Johnson (J&J)
Kyorin Pharmaceutical
Lupin
Massachusetts Biologic Laboratories
Mayne Pharma
Medarex (part of Bristol-Myers Squibb)
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Medicis
Medison Pharma
Meiji Holdings (parent company of Meiji Seika Pharma)
Meiji Seika Pharma
Merck & Co.
MerLion Pharmaceuticals
Ministry of Health, Labor and Welfare (MHLW)
Mylan
Mylan Seiyaku (a subsidiary of Mylan)
Nabriva Therapeutics
Nanotherapeutics
National Institute of Allergy and Infectious Diseases (NIAID) [US]
Nektar Therapeutics
NestlŠ¹
NeuTec Pharma (part of Novartis, now closed)
Nichi-Iko Pharmaceutical
Nipro Pharma
Novartis
Novexel (part of AstraZeneca)
Optimer Biotechnology (a subsidiary of Optimer)
Optimer Pharmaceuticals
Ortho-McNeil Pharmaceutical (a subsidiary of J&J)
Paratek Pharmaceuticals
Patent and Trademark Office [US]
Peninsula Pharmaceuticals (part of J&J)
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmacia (part of Pfizer)
Pliva (part of Teva)
Proctor & Gamble (P&G)
Protez Pharmaceuticals (part of Novartis, now closed)
Ranbaxy (part of Daiichi Sankyo)
Rib-X Pharmaceuticals
Roche
Rutgers University [US]
Salix Pharmaceuticals
Sandoz (a division of Novartis)
Sanofi
Sawai Pharmaceutical
Schering-Plough (part of Merck & Co)
Scottish Medicines Consortium (SMC)
Senju Pharmaceutical
Sequella
Shantou Meiji Pharmaceuticals (a subsidiary of Meiji Seika Pharma)
Shionogi & Co
Simcere Pharmaceutical Group
State Food and Drug Administration (SFDA) [China]
Stiefel Laboratories (part of GSK)
Strides Arcolab
Sumitomo Pharmaceutical (part of Dainippon Sumitomo)
Sunovion Pharmaceuticals
TaiGen Biotechnology
Taisho Pharmaceutical
Taiyo Yakuhin (Taiyo Pharmaceutical Industry)
Takeda Pharmaceutical
TB Alliance
Tedec-Meiji Farma (a subsidiary of Meiji Seika Pharma)
Tetraphase Pharmaceuticals
Teva Pharmaceutical Industries
The Medicines Company
Theravance
Tibotec Pharmaceuticals (part of Janssen Pharmaceutica)
Towa Pharmaceutical
Toyama Chemical
Trius Therapeutics
Upjohn (part of Pfizer)
Victory Pharma
Vicuron Pharmaceuticals (part of Durata)
ViroPharma
Wakunaga Pharmaceutical
Warner Chilcott
Warner Lambert (part of Pfizer)
Watson Pharmaceuticals
Women First HealthCare
World Health Organization (WHO)
Wyeth Pharmaceuticals (part of Pfizer)
Yale University [US]
Yamanouchi Pharmaceutical (part of Astellas)
Zuellig Pharma
